Relationship between thiazolidinedione use and cardiovascular outcomes and all‐cause mortality among patients with diabetes: a time‐updated propensity analysis
- 23 February 2009
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 18 (6), 437-447
- https://doi.org/10.1002/pds.1722
Abstract
Purpose To investigate the association of the thiazolidinediones (TZDs), rosiglitazone, and pioglitazone, together and individually on the risk of cardiovascular outcomes and all‐cause mortality, using time‐updated propensity score adjusted analysis. Methods We conducted a retrospective cohort study in a large vertically integrated health system in southeast Michigan. Cohort inclusion criteria included adult patients with diabetes treated with oral medications and followed longitudinally within the health system between 1 January 2000 and 1 December 2006. The primary outcome was fatal and non‐fatal acute myocardial infarction (AMI). Secondary outcomes included hospitalizations for congestive heart failure (CHF), fatal, and non‐fatal cerebrovascular accidents (CVA) and transient ischemic attacks (TIA), combined coronary heart disease (CHD) events, and all‐cause mortality. Results 19 171 patients were included in this study. Use of TZDs (adjusted hazard ratio (aHR) with propensity adjustment (PA), 0.92; 95% confidence interval (CI) 0.73–1.17), rosiglitazone (aHR with PA, 1.06; 95%CI 0.66–1.70), and pioglitazone (aHR with PA, 0.91; 95%CI 0.69–1.21) was not associated with a higher risk of AMI. However, pioglitazone use was associated with a reduction in all‐cause mortality (aHR with PA, 0.60; 95%CI 0.42–0.96). Compared with rosiglitazone, pioglitazone use was associated with a lower risk of all outcomes assessed, particularly CHF (p = 0.013) and combined CHD events (p = 0.048). Conclusions Our findings suggest that pioglitazone may have a more favorable risk profile when compared to rosiglitazone, arguing against a singular effect for TZDs on cardiovascular outcomes. Copyright © 2009 John Wiley & Sons, Ltd.This publication has 50 references indexed in Scilit:
- The Rosiglitazone Story — Lessons from an FDA Advisory Committee MeetingThe New England Journal of Medicine, 2007
- Rosiglitazone and myocardial infarction: cause for concern or misleading meta‐analysis?Diabetic Medicine, 2007
- Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim AnalysisThe New England Journal of Medicine, 2007
- Coronary heart disease outcomes in patients receiving antidiabetic agentsPharmacoepidemiology and Drug Safety, 2007
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesThe New England Journal of Medicine, 2007
- Rosiglitazone: seeking a balanced perspectiveThe Lancet, 2007
- The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapyPharmacoepidemiology and Drug Safety, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyThe New England Journal of Medicine, 2006
- Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia EventsJAMA, 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006